Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5)

ユーザーレビュー
製品番号/仕様
価格
数量
AA9-Y2142-100ug
$400.00
AA9-Y2142-1mg
$2770.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Source

    Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) is a mouse monoclonal antibody derived from hybridoma cells fused with SP2/0 myeloma cells and murine B lymphocytes.

  • Antibody Type

    Hybridoma Monoclonal

  • Clone

    28B9C5

  • Isotype

    Mouse IgG1, Kappa

  • Host Species

    Mouse

  • Immunogen

    AAV9

  • Application

    Application
    Recommended Usage
    ELISA
    0.2-2 μg/mL
  • Cross Verification

    This product can specially react with AAV9.
    No reactivity to AAV1/ AAV2/ AAV3/ AAV5/ AAV6/ AAV8.

  • Purification

    Protein A purified / Protein G purified.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Liquid

  • Formulation

    Supplied a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • Bioactivity-ELISA

     AAV9 ELISA

    Immobilized AAV9 at 1E+10capsids/ml (100 μl/well) can bind Monoclonal Anti-Adenoviruses AAV9 Neutralizing Antibody, Mouse IgG1 (28B9C5) (Cat. No. AA9-Y2142) with a linear range of 0.50-30ng/mL (QC tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

AAV9 (Adeno-Associated Virus Serotype 9) is a highly efficient and safe gene therapy vector belonging to the Parvoviridae family. It is characterized by broad tissue tropism, enabling efficient transduction of the heart, liver, skeletal muscle, central nervous system (with the ability to cross the blood-brain barrier), and retina, among others. Compared to other serotypes, AAV9 exhibits stronger systemic diffusion capacity and lower immunogenicity, reducing the risk of host immune rejection. Its single-stranded DNA genome (~4.7 kb) allows long-term stable expression of transgenes but has a limited packaging capacity (≤5 kb).
AAV9 has been utilized in clinical trials for various diseases, such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and familial hypercholesterolemia.

最新の進展

 
お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8